Haemonetics Co. (NYSE:HAE) Holdings Lifted by Stifel Financial Corp

Stifel Financial Corp boosted its holdings in Haemonetics Co. (NYSE:HAE) by 87.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,770 shares of the medical instruments supplier’s stock after acquiring an additional 6,425 shares during the quarter. Stifel Financial Corp’s holdings in Haemonetics were worth $1,107,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in HAE. Thrivent Financial for Lutherans lifted its stake in Haemonetics by 6,573.6% during the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after purchasing an additional 836,623 shares during the last quarter. FMR LLC lifted its position in shares of Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after acquiring an additional 521,640 shares during the last quarter. Mizuho Markets Americas LLC acquired a new stake in shares of Haemonetics during the 2nd quarter valued at $30,080,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Haemonetics by 75.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock worth $63,933,000 after acquiring an additional 343,214 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Haemonetics by 327.0% during the second quarter. The Manufacturers Life Insurance Company now owns 307,564 shares of the medical instruments supplier’s stock worth $25,445,000 after purchasing an additional 235,535 shares during the period. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

HAE has been the subject of several analyst reports. CL King initiated coverage on Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 target price for the company. Bank of America initiated coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective for the company. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a research report on Friday, November 8th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target for the company. Finally, Barrington Research reissued an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research note on Wednesday, December 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Trading Down 1.9 %

Shares of NYSE:HAE opened at $75.44 on Monday. The firm has a fifty day moving average of $81.38 and a two-hundred day moving average of $81.25. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. Haemonetics Co. has a 12-month low of $70.25 and a 12-month high of $97.97. The firm has a market capitalization of $3.79 billion, a P/E ratio of 31.30, a price-to-earnings-growth ratio of 1.29 and a beta of 0.38.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The firm had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. During the same quarter last year, the firm earned $0.99 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. On average, equities analysts expect that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.